Celcuity Inc. (NASDAQ:CELC – Get Free Report) saw a significant growth in short interest in the month of August. As of August 15th, there was short interest totalling 2,490,000 shares, a growth of 10.2% from the July 31st total of 2,260,000 shares. Based on an average daily trading volume, of 386,900 shares, the short-interest ratio is currently 6.4 days.
Wall Street Analyst Weigh In
CELC has been the topic of a number of research analyst reports. Needham & Company LLC restated a “buy” rating and issued a $23.00 target price on shares of Celcuity in a research note on Thursday, August 15th. Leerink Partnrs upgraded shares of Celcuity to a “strong-buy” rating in a research report on Monday, July 22nd. Stifel Nicolaus lowered their target price on shares of Celcuity from $40.00 to $39.00 and set a “buy” rating on the stock in a research note on Thursday, August 15th. HC Wainwright reissued a “buy” rating and issued a $27.00 price target on shares of Celcuity in a research note on Thursday, August 15th. Finally, Craig Hallum restated a “buy” rating and set a $27.00 price objective (up previously from $25.00) on shares of Celcuity in a research report on Thursday, May 16th. Six analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $28.67.
View Our Latest Stock Analysis on CELC
Institutional Inflows and Outflows
Celcuity Trading Down 2.1 %
Shares of CELC traded down $0.34 during mid-day trading on Tuesday, reaching $15.62. The company’s stock had a trading volume of 150,089 shares, compared to its average volume of 282,866. The company has a current ratio of 14.95, a quick ratio of 14.95 and a debt-to-equity ratio of 0.54. Celcuity has a 52 week low of $8.39 and a 52 week high of $22.19. The company’s fifty day moving average price is $17.05 and its two-hundred day moving average price is $16.96. The stock has a market cap of $548.28 million, a PE ratio of -5.90 and a beta of 0.81.
Celcuity (NASDAQ:CELC – Get Free Report) last posted its quarterly earnings results on Wednesday, August 14th. The company reported ($0.62) earnings per share for the quarter, topping the consensus estimate of ($0.71) by $0.09. During the same quarter in the prior year, the company earned ($0.66) earnings per share. On average, analysts predict that Celcuity will post -2.54 earnings per share for the current fiscal year.
About Celcuity
Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.
Recommended Stories
- Five stocks we like better than Celcuity
- NYSE Stocks Give Investors a Variety of Quality Options
- 3 Small Cap Stocks That Insiders Are Buying
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- Analysts Forecast Big Upside for Western Digital—Don’t Miss Out
- How to invest in marijuana stocks in 7 steps
- 3 Must-Own Stocks for Bullish Investors in Today’s Market
Receive News & Ratings for Celcuity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celcuity and related companies with MarketBeat.com's FREE daily email newsletter.